ASCO Annual Meeting: New Approaches For Treatment of Hematologic Malignancies
ASCO Updates Guideline On Antiemetics
New Drug Combination Shrinks Kidney Cancers
Docetaxel, Oxaliplatin Active Against Esophageal Cancer
BRCA2 Carriers Reduced BC Risk By Prophylactic Surgery
Communication Is Key To Clinical Trial Enrollment
FDA Approves Treatment For Late-Stage Cervical Cancer
NCI-Approved Clinical Trials
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - In The Headlines: Private funding can’t replace federal funding—but it can help